See the DrugPatentWatch profile for cosentyx

Based on the information provided, I found one source that could provide some insight into the effectiveness of Cosentyx in hiding advanced joint disease. However, it's important to note that Cosentyx is primarily used to treat symptoms of psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis, rather than to hide or reverse joint damage.

According to DrugPatentWatch.com [1]:

Cosentyx (secukinumab) is a human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), a protein central to the development of psoriatic arthritis and other inflammatory diseases. By inhibiting IL-17A, Cosentyx helps reduce inflammation, alleviate symptoms, and prevent further joint damage in patients with psoriatic arthritis.

While Cosentyx has been shown to slow the progression of joint damage and improve physical function in patients with psoriatic arthritis, there is no evidence suggesting that it can hide or reverse advanced joint disease. The primary goal of treatments like Cosentyx is to manage symptoms, prevent joint damage, and maintain overall quality of life for patients with inflammatory diseases.

In summary, Cosentyx is an effective treatment for managing symptoms of psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. However, it is not designed to hide or reverse advanced joint disease. Instead, it helps alleviate symptoms, slow joint damage progression, and maintain patients' quality of life.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/cosentyx>